University of Virginia researcher Nathan Swami has secured a $1.1 million, four-year grant from the National Institutes of Health to develop microfluidic devices capable of identifying and isolating rare circulating cells. By integrating artificial intelligence with on-chip physical analysis, the project aims to improve diagnostic accuracy for cancer and infectious diseases by capturing cell subpopulations that traditional biopsy methods currently overlook, according to the UVA School of Engineering and Applied Science.
The Challenge of Rare Cell Detection
Current medical diagnostic tools are highly effective at identifying broad cell categories like red blood cells or immune cells. However, according to Nathan Swami, a professor of electrical and computer engineering at UVA, these methods frequently miss small, specialized subpopulations of cells that dictate disease progression and treatment outcomes. These “hidden” cells often represent only a fraction of a total cell population.
Standard biopsy procedures, while useful for analyzing chemical composition—such as DNA and RNA—often fail to isolate live cells for real-time physical observation. Swami’s research focuses on cellular plasticity, or the ability of a cell to physically adapt to new environments. Understanding these physical shifts is crucial for developing targeted therapies that respond to how a disease behaves, not just its chemical makeup.
Did you know?
While traditional biopsies require invasive surgical procedures to collect tissue samples, the technology being developed by Swami’s team could expand the use of “liquid biopsies.” These tests rely on blood or other body fluids to monitor disease, potentially allowing for faster, less invasive clinical decisions.
Integrating AI and Microfluidics
The project, titled “Inline impedance-activated recognition, tracking and sorting system on single-cell biophysical metrics,” moves beyond simple observation. Swami and his team are building microfluidic devices that utilize artificial intelligence to perform large-scale data analysis directly on a microchip.
According to the project specifications, the system will integrate neural-network-based analytics with embedded decision-making hardware. This allows the device to measure the physical properties of a single cell and immediately determine whether that cell should be collected for further study. This real-time computational power is a relatively new development in medical engineering, making this level of high-throughput analysis practical for clinical settings for the first time.
Future Trends in Liquid Biopsy Diagnostics
The transition toward more precise, physical-property-based cell analysis marks a shift in how clinicians might manage patient health. By identifying circulating tumor cells that signal changes in cancer progression, or tracking how immune cells respond to specific infections, this technology could reduce the time between diagnosis and the implementation of a treatment plan.
This research is funded through the NIH’s National Institute of General Medical Sciences via an R01 grant. As one of the most competitive programs for investigator-initiated biomedical research, the grant underscores the importance of interdisciplinary collaboration between engineering and medicine. The project is scheduled to run through March 2030.
Frequently Asked Questions
- What is a liquid biopsy?
A liquid biopsy is a diagnostic test that uses blood or other accessible fluids to monitor disease progression or treatment response rather than relying on more invasive surgical biopsy procedures to collect tissue samples. - Why are rare cells important to study?
Even if they represent a tiny fraction of total cell counts, rare cells can drive disease progression, influence how a patient responds to treatment, and play a major role in immunity. - How does AI assist in this research?
The AI-powered computational tools allow the system to analyze massive amounts of data in real-time, enabling the microchip to “decide” which specific cells to isolate for further analysis.
Are you interested in the intersection of engineering and medicine? Subscribe to our research newsletter for the latest updates on breakthroughs in biotechnology and clinical diagnostics.
Worth a look